Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR(R) to Marketing Partner Prasco, LLC
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR(R) to Marketing Partner Prasco, LLC
NORTHVALE, NJ / ACCESSWIRE / December 12, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced the first shipment of generic Adderall XR to its distribution and marketing partner Prasco, LLC ("Prasco"). Adderall XR is an extended-release mixed salt of a single entity Amphetamine product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate) with strengths of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg capsules (the "Products").
新澤西州諾斯維爾/ACCESSWIRE/2023年12月12日/開發利基仿製藥的專業製藥公司Elite Pharmicals, Inc.（“精英” 或 “公司”）（OTCQB: ELTP）今天宣佈向其分銷和營銷合作伙伴Prasco, LLC（“Prasco”）首次發貨仿製藥Adderall XR。Adderall XR 是單體苯丙胺產品（糖精右旋苯丙胺、天冬氨酸、硫酸右旋苯丙胺、硫酸苯丙胺）的緩釋混合鹽，其濃度爲 5 mg、10 mg、15 mg、20 mg、25 mg 和 30 mg 膠囊（“產品”）。
Prasco is, pursuant to the manufacturing and supply agreement dated April 5, 2023 ("Agreement") between the companies, a non-exclusive U.S. distributor of the Products. Prasco will market the Products under Burel Pharmaceutical's label, and Elite will manufacture the Products. Elite's product is co-owned with Mikah Pharma.
根據兩家公司於2023年4月5日簽訂的製造和供應協議（“協議”），Prasco是產品的非獨家美國分銷商。Prasco將以Burel Pharmaceutical的標籤銷售這些產品，而Elite將生產這些產品。Elite的產品與Mikah Pharma共同擁有。
About Prasco, LLC
Prasco is a privately held healthcare company located in Mason, Ohio. Over 50 of the most innovative and trusted pharmaceutical companies have relied on Prasco to bring their products to the US generic marketplace. Prasco provides patients with high-quality products at affordable prices in over 60,000 US pharmacies. For more information, visit the company's website at .
關於 Prasco, LLC
Prasco是一傢俬人控股的醫療保健公司，位於俄亥俄州梅森。50多家最具創新性和最值得信賴的製藥公司都依靠Prasco將其產品推向美國仿製藥市場。Prasco 在美國超過 60,000 家藥店以實惠的價格爲患者提供高質量的產品。欲了解更多信息，請訪問該公司的網站，網址爲。
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products. Elite's product lines consist of immediate-release and controlled-release, solid oral dose products, which are marketed under the Elite Laboratories label, as well as pursuant to licenses granted to third-party pharmaceutical marketing and distribution organizations. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit .
關於精英制藥有限公司
Elite Pharmicals, Inc. 是一家開發、製造和分銷利基仿製藥的專業製藥公司。Elite的產品線包括速釋和控釋固體口服劑量產品，這些產品以Elite Laboratories的標籤銷售，並根據授予第三方藥品營銷和分銷組織的許可證進行銷售。Elite在新澤西州諾斯維爾經營一家經cGMP和DEA註冊的研究、開發和製造工廠。欲了解更多信息，請訪問。
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
本新聞稿包含1995年《私人證券訴訟改革法》所指的 “前瞻性陳述”，包括但不限於與可能與本新聞稿主題有一定關聯的對未來業績、業績或其他預期的影響（如果有）有關的陳述。提醒讀者，此類前瞻性陳述涉及但不限於Elite無法控制的風險、不確定性和其他因素，這可能導致Elite的實際業績、業績或成就與這些前瞻性陳述可能暗示的業績、業績或其他預期存在重大差異。這些前瞻性陳述可能包括關於美國食品和藥物管理局批准產品的預期時間（如果有的話）的陳述，以及FDA爲獲得此類批准而可能要求Elite採取的行動。這些前瞻性陳述不能保證未來的行動或業績。Elite向美國證券交易委員會提交的文件，包括其關於10-K、10-Q和8-K表的報告，無限制地討論了這些風險和其他因素。無論是由於新信息、未來事件還是其他原因，Elite都沒有義務更新或修改其前瞻性陳述。
CONTACT:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
聯繫人：
適用於精英制藥公司
戴安娜·威爾，投資者關係，518-398-6222
Dianne@elitepharma.com
SOURCE: Elite Pharmaceuticals, Inc.
來源：精英制藥公司
譯文內容由第三人軟體翻譯。